EGEN, Inc. Announces the Promotion of Jason Fewell, Ph.D., to Vice-President of Preclinical Research and Development

HUNTSVILLE, Ala., Aug. 7 /PRNewswire/ -- EGEN, Inc. (EGEN), a biopharmaceutical company specializing in nucleic acid therapeutics and delivery, announced today that Jason Fewell, Ph.D., has been promoted from Director of Biology and Pharmacology to Vice-President of Preclinical Research ...

One of the Nation's Leading Analytical Testing Laboratories is Now Easier to Access -- Pace Analytical Launches New Web Site to Showcase Its Three Business Divisions

Pace Analytical Services, Inc. Is Pleased To Announce The Launch Of Its New And Improved Website. The New Site Provides Users With A Comprehensive Overview Of Pace Analytical And Incorporates A More User-Friendly Design Layout To Enhance Functionality And Navigation. The Site Also Offers An Expan...

Transposagen Creates a Rat Model of the Human Immune System

LEXINGTON, Ky. , Aug. 6 /PRNewswire/ -- Transposagen Biopharmaceuticals, Inc. based in Lexington, KY announced today that its scientists and collaborators from the Medical College of Wisconsin have created and characterized the world's first rat model of severe combined immunodefi...

PharmatrophiX, Initially Funded by the Alzheimer's Drug Discovery Foundation, Announces Exclusive Global Collaboration with Elan

Promise of revolutionary orally-administered drugs to combat Alzheimer's began journey 8 years ago "Finding a needle in a haystack - 4 molecules out of a million" NEW YORK, Aug. 6 /PRNewswire-USNewswire/ -- New therapeutics funded by the Alzheimer's Dr...

Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305

CAMBRIDGE, Massachusetts and LAUSANNE, Switzerland, August 6 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS ), a drug development company focused on developing proprietary targeted medicines for cancer treatment and Debiopharm Group (Debiopharm), a group of companies with a focus on the developme...

Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009

VANCOUVER, Aug. 6 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI , TSX: ANP) today announced its financial results for the second quarter ended June 30, 2009. "We were pleased to observe continued sales growth in our Proprietary Medical Products business during the quar...

Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval

SEATTLE, Aug. 6 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today reported recent achievements and financial results for the second quarter and six months ended June 30, 2009. "The second quarter of 2009 was a transforming quarter for the Co...

CapitalBio Corporation and VigeneTech Inc. Have Announced the Launch of a Fully Integrated Microarray Solution Platform

CARLISLE, Mass., Aug. 5 /PRNewswire/ -- CapitalBio Corporation and VigeneTech Inc. have announced the launch of a fully integrated microarray solution platform. CapitalBio Corp., a developer and marketer of diagnostic biochips and advanced microarray instrument systems, in collaboration with ...

The Foundation for National Institutes of Health Announces Unprecedented Product Donation by sanofi-aventis in the U.S.

BETHESDA, Md. and BRIDGEWATER, N.J., Aug. 5 /PRNewswire-FirstCall/ -- Today, the Foundation for the National Institutes of Health and sanofi-aventis announced an unprecedented donation by the global pharmaceutical leader providing approximately $1.3 million in pharmaceutical th...

Pharmacy Compounds Liquid Mupirocin for the Chronic Sinusitis Patient

ASL Pharmacy® announces the availability of Compounded Mupirocin Liquid. Mupirocin is typically only found in ointment form. ASL's compound does not contain any added ingredients, only pure mupirocin, sterile water and sterile saline. This is significant because ASL serves patients with chron...

Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist

JERUSALEM, Israel, August 4 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a developer of oral delivery systems, today reported that its wholly owned Israeli subsidiary, Oramed Ltd., was awarded a government grant amounting to a total net amo...

Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure

SAN FRANCISCO, Aug. 4 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX ), a company focused on the development of novel therapeutics for heart failure patients, today announced dosing of its first patient in a Phase 2 clinical study of its lead product, CD-NP, for the treatme...

VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference

MOUNTAIN VIEW, Calif., Aug. 4 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS ), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that Timothy Morris, chief financial officer, will present an overview of the ...

Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference

SAN DIEGO, Aug. 4 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) is scheduled to present at the Canaccord Adams 29th Annual Global Growth Conference at the Intercontinental Hotel in Boston on August 13, 2009, 2:00 p.m. Eastern Time. (Logo: http://w...

DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD

PRINCETON, N.J., Aug. 4 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc., (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biopharmaceutical company, announced today that the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) has granted Or...

AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma

QUEBEC CITY, Aug. 3 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS , TSX: AEZ), ("the Company") a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ), its partner and licensee for perifosi...

Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States

STAMFORD, Conn. and PT. RICHMOND, Calif., Aug. 2 /PRNewswire-FirstCall/ -- Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT ) today announced entry into an exclusive license and collaboration agreement to commercialize Intermezzo ((R)) (z...

Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City

SAN CARLOS, Calif., July 31 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) is scheduled to present at the upcoming BMO Capital Markets 9th Annual Focus on Healthcare Conference at the Millennium Broadway Hotel in New York City on Wednesday, August 5, 2009 at 1:45 p.m. ...

Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets

SAN CARLOS, Calif., July 31 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the second quarter ended June 30, 2009 on Tuesday, August 4, 2009, after the close of U.S.-based financial markets. Howard Robin, president and chief execut...

SmartGene's Services for Faster, More Precise Identification of Bacteria and Fungi to be Used by The Johns Hopkins Hospital

RALEIGH, N.C. , July 30 /PRNewswire/ -- SmartGene, Inc., a provider of novel services for the management and analysis of genetic data, today announced that it has entered into an agreement under which The Johns Hopkins Hospital will utilize SmartGene's advanced technology and integrated...

Sunesis Receives Approval for Listing on The NASDAQ Capital Market

SOUTH SAN FRANCISCO, Calif., July 30 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced th...

Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009

PITTSBURGH, July 30 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL ) today announced its financial results for the three and six months ended June 30, 2009. Financial Highlights Adjusted diluted EPS, which excludes the impact of certain purchase acc...

"Over the Next 2-3 Years We Will Leverage Developmental Capabilities and Explore In-licensing and a Co-development Model to Consolidate Our Presence in Japan" - Dr. Kailash Sharma, President, Japan Operations, Zydus Cadila

TOKYO, July 30 /PRNewswire/ -- With a business plan to launch 8-10 new products each year, Nippon Universal Pharmaceutical Co. Ltd., a subsidiary of the Zydus group, one of India's leading integrated pharma companies & a global healthcare provider, is looking to give a big boost to its ope...

NIST scientists study how to stack the deck for organic solar power

A new class of economically viable solar power cellscheap, flexible and easy to makehas come a step closer to reality as a result of recent work* at the National Institute of Standards and Technology (NIST), where scientists have deepened their understanding of the complex organic films at the hea...

BP and Verenium Announce Vercipia Biofuels to Advance the Commercialization of Cellulosic Ethanol

CAMBRIDGE, Mass., July 29 /PRNewswire-FirstCall/ -- BP and Verenium Corporation (Nasdaq: VRNM ) today announced that its 50-50 joint venture company will operate under the name Vercipia Biofuels, and plan to relocate its corporate headquarters to Florida. Vercipia continues to foc...

Sunesis Reports Financial Results for the Second Quarter 2009

SOUTH SAN FRANCISCO, Calif., July 29 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) today reported financial results for the second quarter ended June 30, 2009. Total revenue for the second quarter of 2009 was $3.5 million, with a net loss of $22.9 ...

United States FDA Clears the REGEN Trial to Test Bioheart's Combination Gene and Stem Cell Therapy in Heart Failure Patients

SUNRISE, Fla., July 28 /PRNewswire-FirstCall/ -- Bioheart, Inc., (OTC Bulletin Board: BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases announced today that the US FDA cleared a p...

GreenHouse Debuts the World's First E-Fuel MicroFuelerTM in Los Angeles

Basketball Great Shaquille O'Neal, Green Celebrities and Other Investors to Attend July 30 Debut Los Angeles, CA (Vocus) - GreenHouse announced today that on July 30, 2009 it will introduce the revolutionary E-Fuel MicroFuelerTM, a portable in-home micro-refinery syste...

Patton Medical Devices Partners With Unomedical to Develop and Market the i-port Advance(TM) Injection Port for People Taking Multiple Daily Injections

AUSTIN, Texas, July 27 /PRNewswire/ -- Patton Medical Devices, manufacturer of the i-port(R) and a leader of injection port therapy, announced today that they have entered into a partnership agreement with Unomedical, a leading manufacturer of single use medical devices used in th...

PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group

NES-ZIONA, Israel, July 24 /PRNewswire-FirstCall/ -- PROLOR Biotech, Inc. (OTC Bulletin Board: PBTH), formerly Modigene Inc., today announced that it has entered into stock purchase agreements with private investors to sell up to $10 million of the company's newl...

Growing Awareness and Increased Investments Lead to Growth of Biotechnology Applications in the Food & Beverage and Dietary Supplements Sector, Reveals Frost & Sullivan

MUMBAI, July 24 /PRNewswire/ -- - Frost & Sullivan's Food & Beverage Focus 2009 Annual Executive MindXchange on Biotechnology Applications in the Food & Beverage and Dietary Supplements Sector The Indian food processing industry has seen some spectacular product devel...

OMT announces a breakthrough in the development of a novel human antibody platform

Palo Alto, CA: July 23, 2009 Open Monoclonal Technology, Inc. (OMT), in collaboration with Sangamo BioSciences, Inc. (NASDAQ, SGMO), Sigma-Aldrich Corporation (NASDAQ: SIAL), The Medical College of Wisconsin, and INSERM, today announced the creation of the first targeted knockout rats as detaile...

Genetically engineered bacteria compute the route

US researchers have created 'bacterial computers' with the potential to solve complicated mathematics problems. The findings of the research, published in BioMed Central's open access Journal of Biological Engineering , demonstrate that computing in living cells is feasible, opening the door to a...

Peregrine Pharmaceuticals to Present at the Jesup & Lamont 2009 Growth Stock & National Sales Conference

TUSTIN, Calif., July 23 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today announced that senior management will present at the Jesup & Lamont 2009 Growth Stock & National Sales Conference on Thursday, July 30, 2009 at 8:30 am EDT at the Boca Raton ...

Vistaar and the Professional Pricing Society Partner to Present Premier Symposium for Pricing Practitioners

Renowned pricing expert and industry thought leader Dr. Reed Holden to present the keynote address Parsipany, NJ (PRWEB) July 22, 2009 -- Vistaar Technologies, Inc. Vistaar Technologies, a leading provider of pricing software for sales, marketing and finance groups, t...

Alexandria Real Estate Equities, Inc. Signs Biopharmaceutical Company, Lilly, as Anchor New York City Tenant at the Alexandria Center for Science and Technology

PASADENA, Calif., July 22 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE ), Landlord of Choice to the Life Science Industry(R), announced today that an affiliate has entered into a long-term lease with Eli Lilly and Company as the anchor tenant at the Alexan...

Thomson Reuters Announces 2009 Edition of the CMR International Pharmaceutical R&D Factbook

PHILADELPHIA and LONDON, July 22 /PRNewswire/ -- The 2009 edition of the trusted and often cited compendium of pharmaceutical research and development statistics, the CMR International Pharmaceutical R&D Factbook , is now available. This year's Factbook offers extended cont...

University of Lodz Invests in the Unique Cellaxess(R)HT System for Research on Multidrug Resistance Genes in Cancer

GOTHENBURG, Sweden, July 22 /PRNewswire/ -- Cellectricon, a leading provider of cell-based screening solutions for research and drug discovery, today announced its collaboration with University of Lodz, Poland. Under the agreement University of Lodz invests in Cellaxess(R)HT, the world's first...

Axial Biotech Enters Partnership with the University of Utah to Utilize the Utah Population Database to Develop Personalized Diagnostic Tests for Spine Disorders

SALT LAKE CITY, July 22 /PRNewswire/ -- Axial Biotech, Inc., a company personalizing spine care through the development of molecular diagnostics, and the University of Utah today announced that they have entered into a collaboration that allows Axial access to the University's rich ...

Tobira Therapeutics Inc. Announces Phase I Data Demonstrating Pharmacokinetic Properties of TAK-652 for the Treatment of HIV

PRINCETON, N.J. and SAN DIEGO, July 22 /PRNewswire/ -- Tobira Therapeutics Inc., a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced pharmacokinetic data and result...